Literature DB >> 27224897

Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.

B Sofen1, G Prado2, J Emer3.   

Abstract

Dyschromia is a leading cause for cosmetic consultation, especially in those with diverse skin types (mixture of ethnicities) and with the rise of non-core and untrained physicians performing cosmetic procedures. Melasma and post-inflammatory hyperpigmentation (PIH) account for the majority of cases and are characterized by pigmented macules and patches distributed symmetrically in sun-exposed areas of the forehead, cheeks, and chin in melasma, and irregularly in areas of inflammation or an inciting traumatic event with PIH. Treatment is challenging and focused on a variety of mechanisms to stop, hinder, and/or prevent steps in the pigment production (melanocytic hyperactivity) process, breaking down deposited pigment for internal removal or external release, exfoliating cells to enhance turnover, and decreasing inflammation. Topical lightening therapy in combination with sun protection is essential for potential improvement. The most commonly prescribed and researched topical lightening agents are hydroquinone (HQ), azelaic acid (AzA), and retinoids - although only HQ and a triple combination cream (Tri-Luma®; fluocinolone acetonide 0.01%, HQ 4%, tretinoin 0.05%) are US FDA-approved for "bleaching of hyperpigmented skin" (HQ) and "melasma" (Tri-Luma®). Numerous non-HQ brightening/lightening agents, including antioxidant and botanical cosmeceuticals, have recently flooded the market with improvements that claim less irritant potential, as well as avoiding the stigmata associated with HQ agents such as carcinogenesis and cutaneous ochronosis. Combining topical therapy with procedures such as chemical peels, intense pulsed light (IPL), fractional non-ablative lasers or radiofrequency, pigment lasers (microsecond, picosecond, Q-switched), and microneedling, enhances results. With proper treatment, melasma can be controlled, improved, and maintained; alternatively, PIH can be cured in most cases. Herein, we review treatments for both conditions and provide an opinion on proper management for enhanced results.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27224897

Source DB:  PubMed          Journal:  Skin Therapy Lett        ISSN: 1201-5989


  11 in total

1.  Dual Effect of Photobiomodulation on Melasma: Downregulation of Hyperpigmentation and Enhanced Solar Resistance-A Pilot Study.

Authors:  Daniel Barolet
Journal:  J Clin Aesthet Dermatol       Date:  2018-04-01

2.  Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.

Authors:  Bahir H Chamseddin; La'Nette Hernandez; Dezehree Solorzano; Juan Vega; Lu Q Le
Journal:  JCI Insight       Date:  2019-04-30

3.  Trichloroacetic acid model to accurately capture the efficacy of treatments for postinflammatory hyperpigmentation.

Authors:  Alexis B Lyons; Indermeet Kohli; Amanda F Nahhas; Taylor L Braunberger; Tasneem F Mohammad; Cynthia L Nicholson; Nathan T Nartker; Krishna Modi; Mary S Matsui; Henry W Lim; Iltefat H Hamzavi
Journal:  Arch Dermatol Res       Date:  2020-04-06       Impact factor: 3.017

Review 4.  Managing Post-inflammatory Hyperpigmentation in Patients with Acne.

Authors:  Archana M Sangha
Journal:  J Clin Aesthet Dermatol       Date:  2021-06-01

5.  Evaluation of Efficacy and Safety of Low-Fluence Q-Switched 1064-nm Laser in Infra-orbital Hyperpigmentation Based on Biometric Parameters.

Authors:  Shiva Alavi; Azadeh Goodarzi; Mohammad Ali Nilforoushzadeh; Parvin Mansouri; Mohammad Amin Jafari; Somayeh Hejazi; Zahra Azizian
Journal:  J Lasers Med Sci       Date:  2022-04-12

6.  Quantitative Evaluation of the Effectiveness of Chemical Peelings in Reducing Acne Lesions Based on Gray-Level Co-Occurrence Matrix (GLCM).

Authors:  Wiktoria Odrzywołek; Anna Deda; Julita Zdrada; Sławomir Wilczyński; Barbara Błońska-Fajfrowska; Aleksandra Lipka-Trawińska
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-12

7.  Involvement of Transient Receptor Potential Cation Channel Member A1 activation in the irritation and pain response elicited by skin-lightening reagent hydroquinone.

Authors:  Yan Tai; Chuan Wang; Zhihua Wang; Yi Liang; Junying Du; Dongwei He; Xiaoyan Fan; Sven-Eric Jordt; Boyi Liu
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

8.  Combination of Hydroquinone and Fractional CO2 Laser versus Hydroquinone Monotherapy in Melasma Treatment: A Randomized, Single-blinded, Split-face Clinical Trial.

Authors:  Sanaz Nourmohammadi Abadchi; Farahnaz Fatemi Naeini; Elham Beheshtian
Journal:  Indian J Dermatol       Date:  2019 Mar-Apr       Impact factor: 1.494

9.  Prospective Study of Growth Factor Concentrate Therapy for Treatment of Melasma.

Authors:  Bindu Sthalekar; Madhuri Agarwal; Vijay Sharma; Chetan Y Patil; Maulek Desai
Journal:  Indian Dermatol Online J       Date:  2021-07-14

10.  A Randomized, Double Blinded, Split-Face Study of the Efficacy of Using a Broad Spectrum Sunscreen with Anti-Inflammatory Agent to Reduce Post Inflammatory Hyperpigmentation After Picosecond Laser.

Authors:  Thanaporn Puaratanaarunkon; Pravit Asawanonda
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.